Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular ...

Monjuvi previously received FDA approval in July 2020 for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma in combination with lenalidomide.

Follicular lymphoma is a form of non-Hodgkin lymphoma. It’s usually slow-growing and responds well to treatment but is difficult to cure. Since it is a slow-moving cancer, doctors and patients ...

A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.

Long-term data confirms early rituximab significantly delays new treatment for advanced, asymptomatic, low-burden follicular lymphoma compared to watchful waiting. Maintenance rituximab showed no ...

The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with ...

Long-term results of a phase 3 trial show that early rituximab monotherapy significantly delays the need for new treatment in patients with asymptomatic, low tumour burden follicular lymphoma.

We’ve long known follicular lymphoma (FL) as a slow-growing, incurable disease that tends to relapse. For many patients, that has meant cycling through treatments over decades, each remission a ...

In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

WebMD explains the causes, symptoms, and treatment of follicular lymphoma, a type of cancer.